Chiodi Debora, Ishihara Yoshihiro
Department of Chemistry, Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States.
Department of Chemistry, Genesis Therapeutics, 11568 Sorrento Valley Road Suite 8, San Diego, California 92121, United States.
J Med Chem. 2025 Apr 24;68(8):7889-7913. doi: 10.1021/acs.jmedchem.4c03078. Epub 2025 Apr 15.
Among the smaller substituents in the medicinal chemist's toolbox, the hydroxy (OH) group can bestow one of the largest impacts in the drug-like properties of a molecule. A previous study showed that an H-to-OH structural modification effectively decreases lipophilicity, increases solubility, and decreases hERG inhibition. Despite these benefits, an OH group is not always recommended in drug molecules because it presents a metabolic "soft spot" for oxidation and glucuronidation in primary and secondary alcohols. Furthermore, the OH group presents challenges in permeability. In contrast, tertiary alcohols (3° ROH) often display an improved metabolic profile because oxidation at the 3° ROH is not possible, and the geminal alkyl groups could sterically shield the OH group from glucuronidation and permeability challenges. Through a series of matched molecular pairs, this Perspective highlights the 3° ROH as a motif that can reap the benefits but minimize the drawbacks of hydroxy groups in drug discovery.
在药物化学家的工具库中较小的取代基中,羟基(OH)对分子的类药性质可能产生最大的影响之一。先前的一项研究表明,从氢(H)到羟基(OH)的结构修饰能有效降低亲脂性、增加溶解度并减少人醚 - 去极化相关基因(hERG)抑制作用。尽管有这些益处,但药物分子中并不总是推荐引入羟基,因为它是伯醇和仲醇氧化及葡萄糖醛酸化代谢的“弱点”。此外,羟基在渗透性方面也存在挑战。相比之下,叔醇(3° ROH)通常表现出改善的代谢特征,因为3° ROH无法发生氧化反应,且偕二烷基可以在空间上保护羟基免受葡萄糖醛酸化和渗透性挑战。通过一系列匹配的分子对,本综述强调了叔醇(3° ROH)作为一种基序,在药物发现中可以收获羟基的益处,同时将其缺点降至最低。